NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
University of Washington
University of Texas Southwestern Medical Center
Children's Hospital of Philadelphia
Memorial Sloan Kettering Cancer Center
Fundación de investigación HM
Northwestern University
St. Jude Children's Research Hospital
Massachusetts General Hospital
Dana-Farber Cancer Institute
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Asan Medical Center
Memorial Sloan Kettering Cancer Center
Children's Hospital of Philadelphia
Institute of Mother and Child, Warsaw, Poland
Peking University People's Hospital
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
Mayo Clinic
University of Florida
MedSIR
Royal Marsden NHS Foundation Trust
Dana-Farber Cancer Institute
University of Florida
Essen Biotech
Royal Marsden NHS Foundation Trust
Centre Leon Berard
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
University of Iowa
University of Alabama at Birmingham
M.D. Anderson Cancer Center
Institut Bergonié
Swiss Cancer Institute
Shanghai 6th People's Hospital
M.D. Anderson Cancer Center
Sarcoma Alliance for Research through Collaboration
National Taiwan University Hospital
Memorial Sloan Kettering Cancer Center
Hadassah Medical Organization
M.D. Anderson Cancer Center
Massachusetts General Hospital
Essen Biotech
University of California, Irvine
Children's National Research Institute
Roswell Park Cancer Institute
Cancer Research UK
Montefiore Medical Center
Esperas Pharma Inc.